Tirzepatide is a prescription-only, once-weekly injectable medication that may be included in clinician-led weight management programs following a medical evaluation. It was originally developed for the treatment of type 2 diabetes and acts on two incretin receptors: GIP and GLP-1.
In appropriate patients, it may be considered as part of a broader, medically supervised approach to weight management for adults with obesity or excess weight who have associated health considerations.